Lucid Diagnostics Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage cancer prevention medical diagnostics company focused on early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD). The company offers EsoGuard Esophageal DNA Test, a laboratory developed test (LDT) that detects esophageal precancer using next-generation sequencing on samples collected via the EsoCheck Esophageal Cell Collection Device, a 510(k)-cleared, non-invasive capsule-based tool for in-office esophageal cell collection; it operates LucidDx Labs Inc., a CLIA-certified, CAP-accredited clinical laboratory licensed by the New York State Department of Health. A subsidiary of PAVmed Inc. (Nasdaq: PAVM), Lucid Diagnostics targets at-risk populations including GERD patients and high-risk groups such as firefighters, with U.S.-focused commercialization supported by partnerships with healthcare networks, fire departments, and municipalities for screening programs. Founded in 2018 and headquartered at 360 Madison Avenue, 25th Floor, New York, New York, the company maintains a workforce of approximately 72 employees. Recent developments include a September 2025 public offering of common stock led by Canaccord Genuity as joint bookrunner to strengthen its balance sheet; a partnership with Hoag health system to launch a comprehensive EsoGuard testing program across digestive health, primary care, and concierge medicine; expansion into three new states projecting up to 15% revenue growth; publication of an NCI-sponsored study in the American Journal of Gastroenterology demonstrating EsoGuard's efficacy in non-symptomatic patients, potentially expanding the addressable market by 70%; and progress toward Medicare reimbursement including a Multi-X Contractor Advisory Committee meeting and final payment determination for EsoGuard.
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of “Moderate Buy” from Analysts
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Lucid Diagnostics Q4 Earnings Call Highlights
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Brokerages
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026